Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
暂无分享,去创建一个
Rachida Lebtahi | Mohamed Bouattour | Christophe Aubé | Emmanuel Itti | Didier Samuel | Alain Luciani | Gilles Chatellier | Boris Guiu | Laurent Castera | A. Luciani | R. Perdrisot | G. Chatellier | M. Ronot | V. Vilgrain | D. Samuel | O. Couturier | E. Assenat | E. Itti | O. Mundler | R. Lebtahi | J. Raoul | J. Seitz | J. Tasu | C. Aubé | F. Oberti | A. Sibert | B. Guiu | L. Castéra | M. Lewin | R. Adam | R. Gérolami | Olivier Couturier | Isabelle Brenot-Rossi | V. Vidal | Vincent Vidal | Valérie Vilgrain | Frédéric Oberti | G. Pageaux | J. Bronowicki | V. Laurent | Jean-Pierre Tasu | Maxime Ronot | René Adam | H. Pereira | Eric Assenat | C. Costentin | M. Bouattour | Olivier Mundler | Annie Sibert | Jean-Pierre Bronowicki | Christine Silvain | René Gerolami | Jean-Luc Raoul | Jean-Francois Seitz | Helena Pereira | Alina Diana Ilonca | Georges-Philippe Pageaux | Wassim Allaham | Hélène Barraud | Valérie Laurent | Elodie Mathias | Rémy Perdrisot | Anthony Sarran | Charlotte Costentin | Maïté Lewin | Aurelia Dinut | C. Silvain | A. Sarran | I. Brenot-Rossi | H. Barraud | Aurélia Dinut | Wassim Allaham | A. Ilonca | E. Mathias | Alina-Diana Ilonca
[1] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] O. Abdel-Rahman,et al. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. , 2016, The Cochrane database of systematic reviews.
[3] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[4] C. Porta,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.
[5] T. Goto,et al. Hepatocellular carcinoma with extrahepatic metastasis , 2011, Cancer.
[6] Pietro Andreone,et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. , 2002, Radiology.
[7] D. Cella,et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Mine,et al. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment , 2016, BMC Cancer.
[9] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[10] Ramon Planas,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.
[11] Ravi Murthy,et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. , 2005, Radiographics : a review publication of the Radiological Society of North America, Inc.
[12] J. Prieto,et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. , 2009, Hepato-gastroenterology.
[13] F. Miller,et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.
[14] A. Benson,et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.
[15] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[16] F. Izzo,et al. Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.
[17] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[18] G. Chatellier,et al. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial , 2014, Trials.
[19] L. Bolondi,et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? , 2013, Journal of vascular and interventional radiology : JVIR.
[20] J. Bruix,et al. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.
[21] B. Sartorius,et al. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. , 2015, Cancer epidemiology.
[22] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[23] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[24] J. Bruix,et al. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects , 2010, Seminars in liver disease.
[25] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[26] W. Lau,et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. , 2012, International journal of radiation oncology, biology, physics.
[27] John Wong,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.
[28] Wolfgang Vogel,et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. , 2009, The oncologist.